[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Download PDF
Figure 1. Risk periods for the self-controlled case series study. AP indicates antipsychotic agent; RAMQ, Régie de l’Assurance Maladie du Québec.

Figure 1. Risk periods for the self-controlled case series study. AP indicates antipsychotic agent; RAMQ, Régie de l’Assurance Maladie du Québec.

Figure 2. One-year myocardial infarction–free survival and incidence of myocardial infarction among community-dwelling older patients with treated dementia in the exposed subcohort (incident users of antipsychotic agents) vs the unexposed subcohort (nonusers).

Figure 2. One-year myocardial infarction–free survival and incidence of myocardial infarction among community-dwelling older patients with treated dementia in the exposed subcohort (incident users of antipsychotic agents) vs the unexposed subcohort (nonusers).

Table 1. Characteristics of Community-Dwelling Older Patients With Treated Dementia in the Exposed Subcohort (Incident Users of Antipsychotic Agents) vs the Unexposed Subcohort (Nonusers)
Table 1. Characteristics of Community-Dwelling Older Patients With Treated Dementia in the Exposed Subcohort (Incident Users of Antipsychotic Agents) vs the Unexposed Subcohort (Nonusers)
Table 2. Retrospective Cohort Study of the Association Between Antipsychotic Use and Myocardial Infarction (MI)
Table 2. Retrospective Cohort Study of the Association Between Antipsychotic Use and Myocardial Infarction (MI)
Table 3. Self-controlled Case Series Study of 804 Incident Cases of Myocardial Infarction (MI) Among New Users of Antipsychotic Agents
Table 3. Self-controlled Case Series Study of 804 Incident Cases of Myocardial Infarction (MI) Among New Users of Antipsychotic Agents
1.
Ferri CP, Prince M, Brayne C,  et al; Alzheimer's Disease International.  Global prevalence of dementia: a Delphi consensus study.  Lancet. 2005;366(9503):2112-2117PubMedArticle
2.
Cohen-Mansfield J, Taylor L, Werner P. Delusions and hallucinations in an adult day care population: a longitudinal study.  Am J Geriatr Psychiatry. 1998;6(2):104-121PubMed
3.
Lövheim H, Karlsson S, Gustafson Y. The use of central nervous system drugs and analgesics among very old people with and without dementia.  Pharmacoepidemiol Drug Saf. 2008;17(9):912-918PubMedArticle
4.
Gruber-Baldini AL, Stuart B, Zuckerman IH, Simoni-Wastila L, Miller R. Treatment of dementia in community-dwelling and institutionalized Medicare beneficiaries.  J Am Geriatr Soc. 2007;55(10):1508-1516PubMedArticle
5.
Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis.  CMAJ. 2008;179(5):438-446PubMedArticle
6.
De Deyn PP, Carrasco MM, Deberdt W,  et al.  Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.  Int J Geriatr Psychiatry. 2004;19(2):115-126PubMedArticle
7.
Brodaty H, Ames D, Snowdon J,  et al.  A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.  J Clin Psychiatry. 2003;64(2):134-143PubMedArticle
8.
Committee on Safety of Medicines.  Atypical Antipsychotic Drugs and Stroke: Message From Professor Gordon Duff, Chairman . London, England: Committee on Safety of Medicine; 2004. CEM/CMO/2004/1
9.
Food and Drug Administration.  Pharmaceutica. J. revision of WARNINGS section for Risperdal (risperidone). April 16, 2003. http://www.fda.gov/Safety/MedWatch/SafetyAlertsforHumanMedicalProducts/ucm153478.htm. Accessed February 1, 2012
10.
Health Canada.  Important drug safety information: RISPERDAL* (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials: Janssen-Ortho Inc. October 11, 2002. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2002/risperdal_hpc-cps-eng.php. Accessed September 2, 2011
11.
Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use.  Arch Intern Med. 2010;170(1):96-103PubMedArticle
12.
Gill SS, Rochon PA, Herrmann N,  et al.  Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study.  BMJ. 2005;330(7489):e445http://www.ncbi.nlm.nih.gov/pmc/articles/PMC549652/?tool=pubmed. Accessed January 27, 2012PubMedArticle
13.
Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.  J Psychopharmacol. 2005;19(5):473-482PubMedArticle
14.
Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study.  BMJ. 2008;337:a1227http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526549/?tool=pubmed. Accessed January 31, 2012PubMedArticle
15.
Rochon PA, Normand SL, Gomes T,  et al.  Antipsychotic therapy and short-term serious events in older adults with dementia.  Arch Intern Med. 2008;168(10):1090-1096PubMedArticle
16.
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.  JAMA. 2005;294(15):1934-1943PubMedArticle
17.
Wang PS, Schneeweiss S, Avorn J,  et al.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications.  N Engl J Med. 2005;353(22):2335-2341PubMedArticle
18.
Gill SS, Bronskill SE, Normand SL,  et al.  Antipsychotic drug use and mortality in older adults with dementia.  Ann Intern Med. 2007;146(11):775-786PubMed
19.
Trifirò G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients.  Pharmacoepidemiol Drug Saf. 2007;16(5):538-544PubMedArticle
20.
Food and Drug Administration.  Information for healthcare providers: antipsychotics. June 16, 2008. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinfromationforpatientsandproviders/ucm124830.htm. Accessed February 1, 2012
21.
Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke?  CNS Drugs. 2005;19(2):91-103PubMedArticle
22.
Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies.  Stat Methods Med Res. 2009;18(1):7-26PubMedArticle
23.
Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study.  BMJ. 2010;341:c4245http://www.bmj.com/content/341/bmj.c4245?view=long&pmid=20858909. Accessed January 27, 2012PubMedArticle
24.
Lindenmayer JP, Czobor P, Volavka J,  et al.  Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.  Am J Psychiatry. 2003;160(2):290-296PubMedArticle
25.
Meyer JM, Davis VG, Goff DC,  et al.  Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.  Schizophr Res. 2008;101(1-3):273-286PubMedArticle
26.
Bentué-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.  CNS Drugs. 2003;17(13):947-963PubMedArticle
27.
Pariente A, Sanctussy DJ, Miremont-Salamé G, Moore N, Haramburu F, Fourrier-Réglat A.l’Association Française des Centres Régionaux de Pharmacovigilance (CRPV).  Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting.  CNS Drugs. 2010;24(1):55-63PubMedArticle
28.
Danenberg HD, Nahir M, Hasin Y. Acute myocardial infarction due to delirium tremens.  Cardiology. 1999;92(2):144PubMedArticle
29.
Inouye SK, Viscoli CM, Horwitz RI, Hurst LD, Tinetti ME. A predictive model for delirium in hospitalized elderly medical patients based on admission characteristics.  Ann Intern Med. 1993;119(6):474-481PubMed
30.
Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research.  J Clin Epidemiol. 1994;47(7):731-737PubMedArticle
Original Investigation
Apr 23, 2012

Antipsychotic Use and Myocardial Infarction in Older Patients With Treated Dementia

Author Affiliations

Author Affiliations: Faculty of Pharmacy, Université de Montreal (Drs Pariente and Moride and Mr Ducruet), and Pharmacoepidemiology Unit, Research Center, University of Montréal Hospital Center (Dr Moride, Mr Ducruet, and Ms Béland), Montreal, Quebec, Canada; Unité 657 (Drs Pariente, Moride, Moore, and Fourrier-Réglat) and Unité 897 (Dr Dartigues), Institut National de la Santé et de la Récherche Médicale, Université Bordeaux Ségalen, and Centre Hospitalier Universitaire de Bordeaux, Pharmacology (Drs Pariente, Moore, and Fourrier-Réglat) and Neurology (Dr Dartigues) Departments, Bordeaux, France; and Department of Mathematics and Statistics, The Open University, Milton Keynes, England (Dr Farrington).

Arch Intern Med. 2012;172(8):648-653. doi:10.1001/archinternmed.2012.28
×